Heterologous boosting with recombinant VSV-846 in BCG-primed mice confers improved protection against Mycobacterium infection
Tuberculosis (TB) remains a major health problem worldwide, and the development of effective vaccines is urgently needed. Vaccination strategies based on heterologous prime–boost protocols using Mycobacterium bovis bacillus Calmette-Guérin (BCG) as primer and modified vaccinia virus Ankara strain ex...
Gorde:
| Egile Nagusiak: | , , |
|---|---|
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
Taylor & Francis Group
2017-04-01
|
| Saila: | Human Vaccines & Immunotherapeutics |
| Gaiak: | |
| Sarrera elektronikoa: | http://dx.doi.org/10.1080/21645515.2016.1261229 |
| Etiketak: |
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|